Compare

Actinium Pharmaceuticals, Inc. vs Connect Biopharma Holdings Ltd vs Serina Therapeutics, Inc. vs Avalo Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearActinium Pharmaceuticals, Inc.
ATNM
Connect Biopharma Holdings Ltd
CNTB
Serina Therapeutics, Inc.
SER
Avalo Therapeutics, Inc.
AVTX
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$90.0K$64.0K$130.0K$59.0K
Revenue growth (YoY)n/a-99.8%+132.1%-86.6%
Gross marginn/an/an/an/a
Operating marginn/mn/mn/mn/m
Net marginn/mn/mn/mn/m
Net income-$33.89M-$55.48M-$19.18M-$78.26M
EPS (Diluted)-$1.09-$1.00-$1.91-$5.84
Operating cash flow-$24.58M-$51.21M-$17.95M-$51.46M
Free cash flow-$24.68M-$51.64M-$18.01Mn/a
Cash & equivalents$48.00M$38.34M$3.06M$15.86M
Total assets$51.77M$56.08M$6.95M$116.46M
Total liabilities$43.94M$14.10M$6.99M$33.41M
Shareholders' equity$7.83M$41.98M-$37.0K$83.05M
Return on year-end equity-432.6%-132.2%n/a-94.2%
Shares outstanding31.20M56.44M10.77M18.51M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearActinium Pharmaceuticals, Inc.Connect Biopharma Holdings LtdSerina Therapeutics, Inc.Avalo Therapeutics, Inc.
Latest$90.0K
Ended 2025-12-31
$64.0K
Ended 2025-12-31
$130.0K
Ended 2025-12-31
$59.0K
Ended 2025-12-31
1 year earliern/a$26.03M
Ended 2024-12-31
$56.0K
Ended 2024-12-31
$441.0K
Ended 2024-12-31
2 years earlier$81.0K
Ended 2023-12-31
$0
Ended 2023-12-31
$3.15M
Ended 2023-12-31
$1.92M
Ended 2023-12-31
3 years earlier$1.03M
Ended 2022-12-31
n/a$34.0K
Ended 2022-12-31
$18.05M
Ended 2022-12-31
4 years earlier$1.14M
Ended 2021-12-31
n/a$144.0K
Ended 2021-12-31
$5.40M
Ended 2021-12-31